Therapeutic Targeting of SLC6A8 Creatine Transporter Suppresses Colon Cancer Progression and Modulates Human Creatine Levels

Scientists reported that RGX-202, an oral small-molecule SLC6A8 transporter inhibitor, robustly inhibited creatine import in vitro and in vivo, reduced intracellular phosphocreatine and ATP levels, and induced tumor apoptosis.